Abstract

Diabetes mellitus is linked with metabolic stress that induces cellular damage and can provoke renal inflammation and fibrotic responses that eventually lead to chronic kidney disease. Because the inflammasome, interleukin 1 (IL-1), IL-1α/IL-β, and IL-1R are central elements of kidney inflammation and pharmacological IL-1R antagonist (IL-1Ra) was shown to prevent or even reverse diabetic nephropathy (DN) in animal models, we explored the intrinsic expression of IL-1 molecules in kidney tissue of DN patients as regulators of renal inflammation. We used biopsies taken from DN patients and controls and show a high level of IL-1α expression in renal tubular epithelial cells, whereas both IL-1 agonistic molecules (i.e., IL-1α and IL-1β) were devoid of the glomeruli. Human proximal tubular kidney HK-2 cells exposed to high glucose (HG) gradually increase the expression of IL-1α but not IL-1β and induce the expression and deposition of extracellular matrix (ECM) proteins. We further demonstrate that in vitro ectopic addition of recombinant IL-1α in low glucose concentration leads to a similar effect as in HG, while supplementing excess amounts of IL-1Ra in HG significantly attenuates the ECM protein overexpression and deposition. Accordingly, inhibition of IL-1α cleaving protease calpain, but not caspapse-1, also strongly reduces ECM protein production by HK-2 cells. Collectively, we demonstrate that IL-1α and not IL-1β, released from renal tubular cells is the key inflammatory molecule responsible for the renal inflammation in DN. Our result suggests that the clinical use of IL-1Ra in DN should be promoted over the individual neutralization of IL-1α or IL-1β in order to achieve better blocking of IL-1R signaling.

Highlights

  • Diabetic nephropathy (DN) or diabetic kidney disease (DKD) is one of the most frequent complications of both types of diabetes mellitus [1], affecting ∼40% of diabetic patients [2]

  • To better understand the pattern and dynamics of the IL1 genes in diabetic nephropathy (DN), we first tested the expression of a panel of interleukin 1 (IL-1) genes (e.g., IL-1α, IL-1β, and IL-1R antagonist (IL-1Ra)) in biopsies taken from patients diagnosed with different stages of DKD

  • IL-1α and not IL-1β transcript levels were shown to be elevated in a mouse model of diabetes mellitus type 2 significantly above wild-type (WT) mice, supporting the notion that IL-1β transcript and protein expression in the kidney predominately originate from infiltrating immune cells and not from any of the kidney cells [20]

Read more

Summary

Introduction

Diabetic nephropathy (DN) or diabetic kidney disease (DKD) is one of the most frequent complications of both types of diabetes mellitus [1], affecting ∼40% of diabetic patients [2]. Diabetic kidney disease is the leading cause of end-stage renal disease (ESRD) [3], accounting for almost 50% of ESRD cases in developed countries [1]. Diabetic kidney disease is clinically defined as progressively increasing proteinuria accompanied by increasing blood pressure and impairment of glomerular filtration. It is characterized by diffuse or nodular glomerulosclerosis and afferent and efferent hyaline arteriolosclerosis [5]. In addition to increased glomerular leakage, is potentially responsible for microalbuminuria in early-stage DKD [7]. Numerous potential damaging agents may cause tubular cells injury by triggering a proinflammatory and profibrotic response [8]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.